Product Information
DABIGATRAN ETEXILATE 150 MG CP is a generic product labeled by Camber Pharmaceuticals Inc., priced at $0.8226 per EA under NDC 31722062260. Its NADAC has been published 192 times since Dec 21, 2022.
FDA first approved this application on May 6, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Camber Pharmaceuticals Inc.NDC
31722062260
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
DABIGATRAN ETEXILATE MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA207961FDA Approved
5/6/2020
TE Code
AB
On Market Since
5/6/2020
Pharmacological Classes
Price Statistics
The NADAC for DABIGATRAN ETEXILATE 150 MG CP has been published 192 times since Dec 21, 2022, and over the history we have for it it has declined 87.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8226 per EA |
|---|---|
| All-time high | $6.9462 (Jul 12, 2023) |
| All-time low | $0.8226 (Aug 19, 2026) |
| 52-week high | $1.2631 |
| 52-week low | $0.8226 |
| Median price | $1.9291 |
| Average price | $2.7531 |
| Largest weekly change | -54.3% (Sep 20, 2023) |
| Weeks tracked | 192 |
| Tracking since | Dec 21, 2022 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of DABIGATRAN ETEXILATE 150 MG CP?
The current National Average Drug Acquisition Cost (NADAC) for DABIGATRAN ETEXILATE 150 MG CP, manufactured by Camber Pharmaceuticals Inc., is $0.8226 per EA (NDC 31722062260), effective Aug 19, 2026.
How has the price of DABIGATRAN ETEXILATE 150 MG CP changed over time?
Over the history we have for it, the NADAC for DABIGATRAN ETEXILATE 150 MG CP has declined 87.7%. It has been tracked across 192 weekly CMS publications since Dec 21, 2022.
What are the highest and lowest recorded NADAC prices for DABIGATRAN ETEXILATE 150 MG CP?
Since Dec 21, 2022, the NADAC for DABIGATRAN ETEXILATE 150 MG CP has ranged from a low of $0.8226 (Aug 19, 2026) to a high of $6.9462 (Jul 12, 2023), with a median of $1.9291 per EA.
Are there cheaper alternatives to DABIGATRAN ETEXILATE 150 MG CP?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as DABIGATRAN ETEXILATE 150 MG CP in a comparable dosage form, but none are currently priced below it.
Who manufactures DABIGATRAN ETEXILATE 150 MG CP?
DABIGATRAN ETEXILATE 150 MG CP (NDC 31722062260) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.